Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil for Vascular Function in Atherosclerosis and Hyperlipidemia
NCT00120718Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jun 2002
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of fasudil in atherosclerosis and hypercholesterolemia, sponsored by Brigham and Women's Hospital. Primary endpoint: Vascular reactivity. Started Jun 2002; status: completed.
02
Drugs
fasudil
03
Conditions
atherosclerosishypercholesterolemia
Beyond the preview
Go deeper on NCT00120718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120718.